MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
3.020
-0.147
-4.64%
After Hours: 3.010 -0.01 -0.33% 18:24 12/05 EST
OPEN
3.180
PREV CLOSE
3.167
HIGH
3.225
LOW
2.980
VOLUME
42.44K
TURNOVER
--
52 WEEK HIGH
63.45
52 WEEK LOW
2.130
MARKET CAP
9.44M
P/E (TTM)
-0.1198
1D
5D
1M
3M
1Y
5Y
1D
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment
TipRanks · 3d ago
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial
TipRanks · 4d ago
BRIEF-Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical
Reuters · 4d ago
Silexion receives positive feedback from German Health Authority for SIL204
TipRanks · 4d ago
Silexion Therapeutics Receives Written Scientific Advice From German Regulator Regarding Proposed Design Of Phase 2/3 Clinical Study For SIL204 For Locally Advanced Pancreatic Cancer
Benzinga · 4d ago
SILEXION THERAPEUTICS CORP - REGULATORY SUBMISSIONS IN ISRAEL BY Q4 2025, GERMANY BY Q1 2026
Reuters · 4d ago
SILEXION THERAPEUTICS CORP - ON TRACK TO INITIATE PHASE 2/3 TRIAL IN H1 2026
Reuters · 4d ago
Silexion Therapeutics Unveils Gene Silencing Breakthroughs Targeting KRAS-Driven Cancers
Reuters · 5d ago
More
About SLXN
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.